About 33 results found for searched term "99-50-3" (0.103 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M11202 | Protocatechuic acid | Metabolite/Endogenous Metabolite |
| 3,4-Dihydroxybenzoic acid, Protocatechuate | ||
| Protocatechuic acid is a natural polyphenol that has a neuroprotective effect. | ||
| M11483 | A 438079 | P2 Receptor |
| A 438079 is A potent, selective P2X7 receptor antagonist with A pIC50 of 6.9. | ||
| M29081 | Bomedemstat | Histone demethylase |
| IMG-7289 | ||
| Bomedemstat (IMG-7289) is an orally active and irreversible lysine-specific demethylase 1 (LSD1) inhibitor. Bomedemstat can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis. | ||
| M1989 | CHIR-99021 HCl | GSK-3 |
| CHIR-99021 hydrochloride；Laduviglusib hydrochloride | ||
| CHIR-99021 HCl (CT99021) is a hydrochloride of CHIR-99021, with IC50 of 10 nM and 6.7 nM for GSK-3α and GSK-3β, respectively. | ||
| M2584 | MDL-29951 | GluR |
| MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo with IC50 value of 0.14 mM ([3H]glycine binding). | ||
| M2913 | Palbociclib Isethionate | CDK |
| PD 0332991 isethionate | ||
| Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 2/3. | ||
| M2927 | PF-04880594 | Raf |
| PF-04880594 is a RAF inhibitor for BRAF/BRAFV599E and c-RAF with IC50 of 0.19 nM/0.13 nM and 0.39 nM, >100-fold selectivity over CSNK1, JNK2/3 and p38. | ||
| M3668 | GDC-0994 | ERK |
| Ravoxertinib | ||
| Ravoxertinib (GDC-0994) is an orally active ERK kinase inhibitor with IC50 of 6.1 nM and 3.1 nM against ERK1 and ERK2, respectively. | ||
| M5123 | Y-39983 dihydrochloride | ROCK |
| Y-33075 dihydrochloride | ||
| Y-39983 (Y-33075) dihydrochloride is a selective ROCK inhibitor with an IC50 of 3.6 nM, derived from Y-27632, inhibited ROCK more potently than Y-27632. | ||
| M5253 | BLU-9931 | FGFR |
| BLU9931 | ||
| BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively. | ||
| M5827 | Oclacitinib maleate | JAK |
| PF-03394197 | ||
| Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, which did not inhibit a panel of 38 non-JAK kinases. | ||
| M9678 | SAR407899 | ROCK |
| SAR407899 is a potent and selective, ATP-competitive ROCK inhibitor with IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and rat ROCK-2, respectively. | ||
| M9875 | ACT-389949 | FPR |
| ACT389949 | ||
| ACT-389949 is a first-in-class, potent, selective formyl peptide receptor 2/lipoprotein A4 receptor (FPR2)/(ALX) agonist with an EC50 value of 3 nM for FPR2/ALX entry into monocytes.Additionally, ACT-389949 is an excellent tool compound for in vitro and in vivo to further analyze FPR2-regulated activity, which could be used in the development of next-generation FPR signaling-regulated anti-inflammatory therapies. | ||
| M10283 | AZD-5991 Racemate | Bcl-2 |
| AZD-5991 Racemate is a Mcl-1 inhibitor with an IC50 of <3 nM in FRET assay. | ||
| M10501 | PT2399 | HIF |
| PT-2399 | ||
| PT2399 is a potent and orally available antagonist of HIF-2 with an IC50 of 6 nM, PT2399 selectively disrupts the heterodimerization of HIF-2α with HIF-1β. | ||
| M13405 | RIPK3-IN-1 | RIPK |
| RIPK3-IN-1 is a RIPK3 TYPE II DFG-out inhibitor with IC50 of 9.1 nM. RIPK3-IN-1 inhibited ABL, BRAF/V599E, MAP4K3 and SRC with IC50 values of 0.37, 0.15, 0.012 and 0.075 μM, respectively. | ||
| M13732 | SAR407899 hydrochloride | ROCK |
| SAR407899 hydrochloride is a selective, potent and ATP-competitive ROCK inhibitor, with an IC50 of 135 nM for ROCK-2, and Kis of 36 nM and 41 nM for human and rat ROCK-2, respectively. | ||
| M14117 | YKL-05-099 | Salt-inducible Kinase |
| YKL-05-099 is a salt-inducible kinase (SIK) inhibitor. YKL-05-099 binds to SIK1 and SIK3 with IC50s of ~10 and ~30 nM, respectively. YKL-05-099 has slightly less potent SIK2-inhibitory (IC50=40 nM). | ||
| M14133 | BMS-599626 Hydrochloride | EGFR/HER2 |
| AC480 Hydrochloride | ||
| BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC50s of 20 and 30 nM, respectively. | ||
| M14153 | Ravoxertinib hydrochloride | ERK |
| GDC-0994 hydrochloride | ||
| Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally bioavailable inhibitor selective for ERK kinase activity with IC50 of 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively. | ||
| M14724 | LY 345899 | Dehydrogenase |
| LY 345899 is a Folate analog and is a methylene tetrahydrofolate dehydrogenase (MTHFD1; DC301) and MTHFD2 inbhibitor with IC50 values of 96 nM and 663 nM, respectively and a Ki of 18 nM for MTHFD1. | ||
| M14767 | SHIN1 | Others |
| RZ-2994 | ||
| SHIN1 (RZ-2994) is a human serine hydroxymethyltransferse 1 and 2 (SHMT1/2) inhibitor with IC50s of 5 and 13 nM, respectively, in an in vitro assay. | ||
| M15108 | FR183998 free base | Na+/H+ Exchanger (NHE) |
| FR183998 free base is a potent Na+/H+-exchange inhibitor, with IC50s of 0.3 nM, 3.1 nM and 6.5 nM by measurement of pHi change in rat lymphocytes, rat and human platelets, respectively. | ||
| M20388 | AC480 (BMS-599626) | EGFR/HER2 |
| AC480 (BMS-599626) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, >100-fold to VEGFR2, c-Kit, Lck, MET etc. Phase 1. | ||
| M20727 | BI 894999 | Epigenetic Reader Domain |
| BI 894999 is a potent and selective BET inhibitor with IC50 of 5 nM and 41 nM for the binding of BRD4-BD1 and BRD4-BD2 to acetylated histones, respectively. BI 894999 is highly selective for BRD2/3/4 and BRDT (Kd of 0.49-1.6 nM), with at least a 200-fold selectivity vs. BRD4-BD1. | ||
| M20791 | Amcinonide | NO Synthase |
| Cyclocort, CL-34699 | ||
| Amcinonide (Cyclocort, CL-34699) is an inhibitor of nitric oxide (NO) release from activated microglia with IC50 of 3.38 nM. | ||
| M21035 | LCH-7749944 | PAK |
| GNF-PF-2356 | ||
| LCH-7749944 (GNF-PF-2356) is a novel and potent p21-activated kinase 4 (PAK4) inhibitor with an IC50 of 14.93 μM and has less potently inhibitory effect against PAK1, PAK5 and PAK6. LCH-7749944 causes successful inhibition of EGFR activity due to its inhibitory effect on PAK4. | ||
| M21386 | Pelecopan | Complement System |
| BCX9930 | ||
| Pelecopan (BCX9930) is a potent, selective complement factor D inhibitor with oral activity and an IC50 value of 14.3 nM. | ||
| M27808 | AZ12799734 | TGF-β Receptor |
| AZ12799734 is a selective, orally active TGFBR1 kinase inhibitor with an IC50 of 47 nM. AZ12799734 is also a pan BMP and TGFβ inhibitor. | ||
| M27929 | BMS-817399 | CCR |
| BMS-817399 is a potent, selective, and orally bioavailable CCR1 antagonist. BMS-817399 exhibits CCR1 binding affinity and chemotaxis inhibition potencies of 1 and 6 nM (IC50), respectively. BMS-817399 can be used for the research of rheumatoid arthritis. | ||
| M28169 | Osilodrostat phosphate | Mineralocorticoid Receptor |
| LCI699 phosphate | ||
| Osilodrostat (LCI699) phosphate is a potent, orally active11β-hydroxylase (CYP11B1) inhibitor with an IC50 value of 35 nM. Osilodrostat phosphate is a potent, orally aldosterone synthase (CYP11B2) inhibitor with IC50 values of 0.7 nM and 160 nM for human aldosterone synthase and rat aldosterone synthase, respectively. Osilodrostat phosphate inhibits aldosterone and corticosterone synthesis. | ||
| M28298 | NCGC00249987 | Phosphatase |
| NCGC00249987 is a highly selective and allosteric Tyr phosphatase activity of Eya2 inhibitor with IC50s of 3 μM and 6.9 μM for Eya2 ED and MBP-Eya2 FL. NCGC00249987 specifically targets migration, invadopodia formation, and invasion of lung cancer cells. | ||
| M28491 | MRT199665 | Salt-inducible Kinase |
| MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC50s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively. MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
